Results 191 to 200 of about 356,273 (249)

Regular Physical Inactivity and Ovarian Cancer Risk in the Ovarian Cancer in Women of African Ancestry Consortium. [PDF]

Cancer Epidemiol Biomarkers Prev
Lima SM, Minlikeeva AN, Johnson CE, Guertin KA, Bandera EV, Zheng W, Bethea TN, Petrick JL, Joslin CE, Myers ER, Harris HR, Peres LC, Setiawan VW, Wu AH, Rosenberg L, Schildkraut JM, Ochs-Balcom HM.   +16 more
europepmc   +1 more source

Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. [PDF]

Adv Biol (Weinh)
Jorgensen A, Vermeer DW, Jung E, Williamson CS, Omran DK, Schwartz LE, Yoon JY, Barr J, Tetlow AL, Trinidad CV, Drapkin R, Godwin AK, Vermeer PD.   +12 more
europepmc   +1 more source

Epithelial Ovarian Cancer With Cardiac Metastases in Pregnancy: A Case Report. [PDF]

Cureus
Quijano T, Puentes L, Mora E.
europepmc   +1 more source

The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding

Animal Research and One Health, EarlyView.
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang, Weiran Wu, Qingqing Cai, Jiaxing Wang, Qi Gao, Muhammad Iftikhar, Yulin Bi, Hao Bai, Lihong Gu, Guobin Chang, Shihao Chen   +10 more
wiley   +1 more source

Cytoreductive surgery for ovarian cancer with pelvic ectopic kidney: a case report. [PDF]

Front Oncol
Kuang M, Cheng X, Wen M, Shen C.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Diagnostic Timing and Ovarian Cancer Survival.

JAMA Netw Open
Soppe SE, Kuo TM, Bae-Jump VL, Albright BB, Lyratzopoulos G, Baggett CD, Thompson CA.   +6 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Identifying the best diagnostic test for ovarian cancer - synopsis of Refining Ovarian Cancer Test accuracy Scores (ROCkeTS) research.

Health Technol Assess
Sundar S, Agarwal R, Scandrett K, Davenport C, Sturdy L, Ottridge R, Deeks J, ROCkeTS collaborators.   +7 more
europepmc   +1 more source